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Abstract
Cattle are an important reservoir of Escherichia coli O157:H7 leading to contamination of food and water, and subsequent human disease. This pathogen colonizes its hosts by producing several proteins such as Tir and EspA that are
secreted by a type III secretion system. These proteins play a role in colonization of the intestine, suggesting that they
might be useful targets for the development of a vaccine to reduce levels of this organism in cattle. Vaccination of cattle with proteins secreted by E. coli O157:H7 significantly reduced the numbers of bacteria shed in feces, the numbers
of animals that shed, and the duration of shedding in an experimental challenge model. Vaccination of cattle also significantly (P=0.04) reduced the prevalence of E. coli O157:H7 in a clinical trial conducted in a typical feedlot setting.
This strategy suggests it is possible to vaccinate cattle to decrease the level of E. coli O157:H7 shedding for the purpose
of reducing the risk of human disease.
Keywords: Enterohemorrhagic Escherichia coli, EHEC, O157:H7, bovine vaccine

evidence suggests that most calves are exposed to E. coli
O157:H7 [8]. The number of animals shedding the organism in their feces is usually higher in the summer months
[9], which correlates with an increased incidence of human
disease. Shedding is intermittent, but it is not known if the
organism remains in the intestines of cattle during periods
of time when it cannot be recovered from feces.
Since cattle and their products are associated with the
majority of cases of E. coli O157:H7 infection in humans,
they represent an attractive target for pre-slaughter intervention as a means of reducing risk to humans. A number
of approaches are being studied to reduce levels of the organism in cattle, including animal management practices
such as chlorination of water [10], modifications to animal
feed [11–13], the use of probiotics [14], and bacteriophage
therapy [15]. Other vaccinations are also being investigated
[16–18].
Proteins secreted by the type III system play a role in
colonization of non-bovine hosts by E. coli O157:H7 [19],

1. Introduction
Enterohemorrhagic Escherichia coli (EHEC) is an important zoonotic pathogen of humans, causing severe diarrhea
(hemorrhagic colitis) and in a small percentage of cases,
haemolytic-uremic syndrome (HUS). There are approximately 75,000 infections and 61 deaths/year in the USA [1].
Unfortunately, antibiotics increase the risk of HUS [2], and
there are no current therapies for EHEC human infections
other than general supportive measures [3]. EHEC serotype
O157:H7 causes 85–95% of the cases of HUS in North America [4], and is also the leading cause of HUS in Europe [3].
Cattle are an important reservoir for E. coli O157:H7
and many human infections are attributable to contact with
contaminated meat or other sources, such as water, fruit or
vegetables [4]. This organism can be found in 80% of some
populations of live cattle [5], and 49% of beef carcasses [6],
respectively. It does not appear to cause disease in adult cattle, although it can cause diarrhea in neonates [7]. Serologic
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and it is likely they are also required for colonization of the
bovine intestine. One virulence determinant, Tir, is integrated into the host cell membrane where it serves as the
receptor for the bacterial outer membrane protein, intimin
[19]. Tir-intimin binding is essential for bacterial adherence
to host cells [19–21]. Proteins secreted via the type III pathway, including Tir, EspA (which forms a linkage between
bacterium and host cell), and EspB (which forms a pore in
the host cell), are recognized by sera from convalescent individuals [22]. Dean-Nystrom et al. [20] demonstrated that
intimin is required for the development of attaching-effacing (A/E) lesions in neonatal calves, and that pedestals
(protrusions beneath adherent bacteria mediated by type
III effectors such as Tir) are present in infected ileal tissue.
Baehler and Moxley [23], by inoculating explants prepared
from 18-month-old slaughtered steers, demonstrated that
adult bovine colonic and rectal epithelia are susceptible to
E. coli O157:H7 induced A/E lesions. Subsequent studies,
based on experimental inoculation of adult cattle, demonstrated that expression of intimin [24] and Tir [25] are required for E. coli O157:H7 intestinal colonization. A study
in swine demonstrated the potential for protection against
A/E lesions and intestinal colonization by vaccination with
intimin [26]. Collectively, these observations suggest that
the type III secreted proteins are attractive targets for vaccine development.

2. Materials and methods
2.1. Bacterial strains and culture conditions
The E. coli O157:H7 strain used for the production of type
III secreted proteins and experimental infection was originally obtained from Li et al. [22] and Tarr et al. [27] and
the tir mutant was described by Li et al. [22]. Recombinant
E. coli K12 strains used for the production of Tir and EspA
were as described [22].
2.2. Preparation of type III secreted proteins and vaccine
formulation
Supernatant proteins [containing type III secreted proteins
(Esps and Tir)] were prepared from E. coli O157:H7 precisely as described [22], and formulated with the adjuvant
VSA3 [28] such that the protein concentration was either
25 or 100 μg/ml.
2.3. Vaccination and experimental infection of cattle
Calves and yearling cattle were obtained from farms in Saskatchewan, Canada and were housed at the University of
Saskatchewan. They were fed a barley-based finishing ration
with free choice roughage. All animals were screened prior
to immunization for existing serum antibody titres against
EHEC secreted proteins as well as shedding of E. coli O157:
H7. Animals which had existing titres or which were shedding the organism at any point prior to experimental chal-
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lenge were excluded from the study and were moved to separate housing to avoid cross-contamination. Cattle were
immunized with 2 ml of each vaccine formulation delivered subcutaneously in the neck. In all experiments, a control vaccine group that received a formulation containing adjuvant only was included. Animals were challenged 2
weeks following the last immunization with 108 CFU of E.
coli O157:H7 by oral-gastric intubation and fecal shedding
of the organism was monitored for 14 days. In the first experiment described below, eight seronegative 6-month-old
calves were vaccinated twice with 2 ml of the vaccine formulation (100 μg/ml) by the subcutaneous route, while an
equal number of age-matched calves received a placebo containing adjuvant but no antigen. Bacteria were detected by
direct plating of fecal samples which had been resuspended
in saline on Sorbitol MacConkey agar supplemented with
cefixime and tellurite [29]. A second vaccine trial was designed in which three groups of yearling (adult) cattle were
immunized as described above three times with 50 μg of supernatant (n=13), 50 μg of secreted proteins from a tir mutant [19] (ΔTir, n=10) or a placebo (n=25) on days 0, 21, and
35. Fecal samples from yearling cattle were cultured after
immunomagnetic enrichment [29 and 30] as well as direct
plating. The immune response following immunization was
measured using serum samples taken at the time of each
vaccination by an enzyme-linked immunosorbent assay
[31] and by Western blotting [22]. Differences in outcome
variables between or among vaccine groups were assessed
using the Wilcoxon Rank Sum Test or the Kruskal–Wallis ANOVA, as appropriate. These differences were considered significant whenever P<0.05. This model typically results in measurable shedding of the organism for a period
of approximately 60 days. All animal experiments were conducted in accordance with the guidelines established by the
Canadian Council for Animal Care.
2.4. Protection against natural exposure to E. coli O157:
H7
One hundred and ninety-two steers were blocked by weight,
stratified by weight within block and assigned randomly to
24 pens on 11 May 2002. The cattle were housed in outdoor
dirt-floored pens with a stocking density of 28 square meters of floor-space per animal. The finishing diet of 54.5%
high moisture corn, 35% wet corn gluten feed, 5% corn silage, 2.5% alfalfa hay, and 3% supplement was used for all
animals. The treatments (vaccination, yes or no) were randomly allocated to four pens within each of three weight
blocks for a total of twelve repetitions per treatment. The
treatments were initiated (treatment day 0) 9, 17, and 23
days after cattle arrived in the feedyard for blocks 1, 2,
and 3, respectively. The vaccine was the same as described
above, consisting of secreted proteins of E. coli O157:H7,
and was administered subcutaneously (50 μg/dose) to cattle within assigned pens on treatment days 0, 21, and 42 of
each block. Cattle within the control pens received an injection of adjuvant on the same schedule as vaccinated cattle.
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Table 1. Oligonucleotide primers used in multiplex PCR to confirm identity of isolates as E. coli O157:H7
Primer

Oligonucleotide sequence (5′–3′)

AE19
AE20

CAGGTCGTCGTGTCTGCTAAA
TCAGCGTGGTTGGATCAACCT

FLICH-7F
FLICH-7R

Target

Reference

1087

eae

[33]

GCGCTGTCGAGTTCTATCGAGC
CAACGGTGACTTTATCGCCATTCC

625

fliCh7

[34]

Stx1F
Stx1R

TTCGCTCTGCAATAGGTA
TTCCCCAGTTCAATGTAAGAT

555

stx1

[35]

O157F
O157R

CGGACATCCATGTGATATGG
TTGCCTATGTACAGCTAATCC

259

rfbEO157:H7

[36]

Stx2F
Stx2R

GTGCCTGTTACTGGGTTTTTCTTC
AGGGGTCGATATCTCTGTCC

118

stx2

[35]

Samples of rectal feces were collected for bacterial culture
from cattle within each block on treatment days 0, 21, 42,
63, 84, and the day of marketing (treatment days 106, 104,
and 105 of blocks 1, 2, and 3, respectively).
Outcome measures were pen-level performance and the
proportion of animals per pen culture-positive for E. coli
O157:H7. Feedlot performance and E. coli O157:H7 culture
outcomes were analyzed after arcsine transformation of the
proportions accounting for block as a random effect and repeated sampling for E. coli O157:H7.
Fecal samples were cultured for E. coli O157:H7 as previously described [5] with modifications. Ten grams fecal
samples were incubated 6 h in 90 ml Gram-negative (GN)
broth containing 8 μg/ml vancomycin, 0.05 μg/ml cefixime, and 10 μg/ml cefsulodin. One ml of this culture was
subjected to O157 immunomagnetic separation (Dynal,
Lake Success, NY), and 20 μl of the bead-bacteria mixture
was spread onto sorbitol-MacConkey plates containing cefixime (0.05 μg/ml) and potassium tellurite (2.5 μg/ml;
CT-SMAC) and cultured overnight. Individual sorbitolnonfermenting colonies were subcultured for isolation on
CT-SMAC plates, and an individual sorbitol-nonfermenting colony from each plate was inoculated onto both MacConkey and Fluorocult (EM Science, Gibbstown, NJ) agars.
Isolates that fermented lactose but not sorbitol within 24 h
and had a negative 4-methylumbelliferyl-β- -glucuronide
(MUG) reaction were streaked for isolation on blood agar
plates. Following overnight incubation, one colony per isolate from a blood agar plate was tested for E. coli O157 and
H7 antigens by latex agglutination (Remel, Lenexa, KS).
Isolates that were positive for O157 antigen by latex agglutination (regardless of H7 results) were tested in a five
primer-pair multiplex polymerase chain reaction (PCR)
assay that detected genes for E. coli O157 (rfbEO157:H7),
H7 (fliCh7), Shigatoxins 1 (stx1) and 2 (stx2), and intimin
(eae). For PCR amplification, cells from an individual colony on blood agar were transferred into a 1.5 ml Eppendorf
tube containing 50 μl sterile nuclease-free water and incubated at 100 °C for 6 min. The tube was then centrifuged
at 2000 rpm for 2 min in a microfuge and the supernatant

Product size (bp)

used as template. For each assay, template prepared from
E. coli O157:H7 strain EDL933 (ATCC #43895) was used as
a positive control, and one lacking any template was used
as a negative control. The PCR was conducted in a 50 μl reaction mixture containing 2 μl template DNA, 10 mM Tris–
HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl2, 200 μM of each
dNTP (Promega, Madison WI), and 1.5 U Taq DNA polymerase (Promega). Oligonucleotide primers (Table 1) were
used at the following concentrations: 0.5 μM for those targeting the eae, stx1, stx2, and rfbEO157:H7 genes, and 0.2 μM
for those targeting the fliCh7 gene. Samples were amplified
in a PTC-200 DNA engine (MJ Research Inc., Incline Village, NV) under the following cycling conditions. Conditions included an initial denaturation step of 5 min at 94 °C,
followed by 34 cycles with denaturing at 94 °C for 45 s, annealing at 50 °C for 30 s, and extension at 72 °C for 90 s.
The final cycle consisted of extension for 10 min at 72 °C,
ramping to 50 °C at 0.1 °C/s, holding 50 °C for 5 min, ramping to 4 °C at 0.2 °C/s, and soaking at 4 °C. Samples were
analyzed by standard agarose gel electrophoresis (10 μl per
sample) on a 1.3% gel, stained with ethidium bromide, and
then visualized under UV illumination. DNA molecular size
standards (PCR marker, Promega, Madison WI) and positive and negative controls were included in every run.

3. Results
To test the vaccine potential of secreted proteins, supernatant proteins [containing type III secreted proteins (Esps
and Tir)] were prepared from E. coli O157:H7, formulated
at a dose of 100 ug/ml and used to vaccinate eight calves.
A second group of calves which received a placebo vaccine
was also included. The group that received the EHEC vaccine showed a 13-fold increase in specific antibody titre to
type III secreted proteins after a single immunization, and
after a booster vaccination on day 21, the EHEC vaccine
group demonstrated a 45-fold increase in specific antibody
titre while only one of the placebo vaccine group seroconverted (χ2, P=0.0002). On each of the post-challenge days,
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Figure 1. Number of calves shedding E. coli O157:H7 on each day following experimental challenge. The strain used for infection [22–27]
was grown to mid-exponential phase as described [22]. Bacteria were
detected by direct plating of fecal samples that had been resuspended
in saline on Sorbitol MacConkey agar supplemented with cefixime and
tellurite [29]. Solid bars, placebo group; hatched bars, EHEC vaccine
group.

fewer EHEC-vaccinated animals shed bacteria compared to
the placebo group (Figure 1). Seven of eight placebo-immunized animals shed the bacteria during the trial and four of
those animals shed for four or more consecutive days. Five
of eight EHEC vaccine-immunized animals shed the bacteria at some point during the trial, but only one shed for
more than two consecutive days, indicating that colonization was transient and significantly less than the placebo
group. The total number of bacteria isolated from fecal
samples was significantly lower among the EHEC-vaccinated group as compared to the placebo group (Wilcoxon
Rank Sum Test, P=0.05), with the former having a median
of 6.25 colony forming units (CFU) per gram of feces recovered compared to a median value of 81.25 CFU/g for the
latter.
No significant differences in anti-EHEC, anti-Tir or
anti-EspA responses were observed between groups of six
calves immunized with 50, 100, or 200 μg of supernatant,
but all three were significantly higher than the placebo
group on days 21 (boost) and 35 [25]. Thus, a second vaccine trial was conducted in which three groups of yearling
cattle were immunized with supernatant prepared from
the wild-type strain (n=13), from a tir mutant [19] (ΔTir,
n=10) or a placebo (n=25) on days 0, 21, and 35, followed
by oral challenge with E. coli O157:H7 on day 49. The group

that received the ΔTir vaccine showed a response of similar
magnitude against total secreted proteins as the group that
received the vaccine prepared from the wild-type strain,
but, as expected, a significantly reduced response to Tir
(Wilcoxon Rank Sum Test, P=0.006) (Table 2). However,
the former group did show an increase in anti-Tir antibody
levels (Wilcoxon Rank Sum Test, P=0.009), indicating either exposure to an organism producing an immunologically-related molecule or natural exposure to E. coli O157:
H7. This is further supported by the observation that there
was an increase in the anti-Tir antibody titre in the placebo
group on the day of challenge (Wilcoxon Rank Sum Test,
P=0.002) but no difference between the placebo or ΔTir
groups (P=0.37, Kruskal–Wallis ANOVA). The response to
EspA, a type III secreted protein, was similar in both the
EHEC and ΔTir vaccine groups (P=0.45, Kruskal–Wallis
ANOVA) and was significantly higher than the placebo-immunized animals (P<0.0001).
The proteins secreted by the type III system were highly
immunogenic in cattle (Figure 2). EspB, EspD and Tir were
all reactive and after the second immunization on day 21,
a significant response against lipopolysaccharide was also
observed. The kinetics of the immune response in a vaccinated animal (Figure 2, bottom panels) show that anti-Tir
antibodies were detectable following a single immunization, as were antibodies against 43 and 100 kDa proteins.
The latter proteins were produced by the wild-type strain as
well as the sepB and tir mutants and the 100 kDa protein is
probably EspP, a non-type III EHEC secreted protein.
After oral challenge with E. coli O157:H7 on day 49,
each group was monitored daily for fecal shedding of the
organism for 14 days. In this experiment, bacteria were cultured after immunomagnetic enrichment [29, 30] rather
than direct plating as yearling cattle shed less than calves in
this infection model. On the day of challenge, two animals
in the placebo group were culture-positive for E. coli O157:
H7 and were eliminated from the trial. The placebo-immunized animals shed the organism after challenge much
more than those in the two EHEC vaccine groups (Figure
3). Animals receiving the placebo shed the organism for a
median of 4 days, significantly longer than the median of 0
day by the other two vaccine groups (P=0.0002, Kruskal–
Wallis ANOVA). Significantly fewer bacteria were recovered
from the EHEC and ΔTir vaccine groups (P=0.04, Kruskal–
Wallis ANOVA). From day 2 post-infection onwards, 78.3%
of the placebo animals (18 of 23 animals) shed the organ-

Table 2. Median serological response of yearling cattle to immunization with secreted proteins prepared from wild-type E. coli
O157:H7 (EHEC), an isogenic tir mutant (ΔTir) or a placebo.
Group

EHEC
ΔTir
Placebo

N

13
10
25

Anti-EHEC

Anti-Tir

Anti-EspA

Day 0

Day 49

Day 0

Day 49

Day 0

Day 49

10 (10–100)
10 (10–100)
10 (10–200)

6400 (3200–12800)
6400 (3200–25600)
10 (10–200)

100 (10–200)
10 (10–200)
100 (10–200)

1600 (800–3200)
200 (100–800)
200 (10–400)

100 (10–200)
100 (10–200)
100 (10–200)

400 (200–1600)
300 (100–1600)
100 (10–200)

Titres are expressed as median values of the last positive dilution of sera [31]. Numbers in parentheses represent the 25th–75th percentile.
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Figure 2. Immunoblot analysis of sera from vaccinated yearling cattle against EHEC secreted proteins. Each blot contains secreted proteins from
wild-type E. coli O157:H7 (EHEC), type III secretion mutant (ΔSepB), tir mutant (ΔTir) and a purified glutathione-s-transferase:Tir fusion protein
(GST-Tir). Proteins were separated by SDS-10% PAGE and stained with Coomassie blue (A, upper left panel) or transferred to nitrocellulose and
probed with representative sera from animals which received three immunizations with each vaccine formulation (A). The lower four panels (B)
were probed with sera from one representative animal which received the EHEC vaccine, taken on days 0, 21, 35 and 49 of the trial (prebleed, after
initial immunization, after boost #1, after boost #2, respectively).

ism for at least 1 day as compared to 15.4% of the EHEC
(2 of 13, P=0.003) and 30% (3 of 10, P=0.008) of the ΔTir
vaccinates.
To determine whether vaccination would have an effect on E. coli O157:H7 infection occurring from natural
exposure, a clinical trial was conducted. Specifically, the
trial evaluated the effect of vaccination on the proportion
of feedlot steers shedding E. coli O157:H7 in their feces in
typical feedlot conditions of exposure. Treatment groups
did not differ in performance (viz. average daily gain, dry
matter intake, gain to feed, marbling score, fat thickness, or
yield grade).
The pre-treatment prevalence of animals shedding E.
coli O157:H7 averaged 30%, and did not differ significantly
between treatments (P=0.66). The average proportion of
cattle shedding E. coli O157:H7 differed (P=0.04) over the
five test-periods (treatment days 21, 42, 63, 84, and the day
of marketing; 24, 10.9, 13.0, 5.7, and 21.4%, respectively);
however, no interaction was observed between treatment
and test-period (P=0.62). The average proportion of cattle shedding E. coli O157:H7 in vaccine treated pens (8.8%)

was significantly less (P=0.04) than in non-vaccinated pens
of cattle (21.3%) (Figure 4). A total of 362 E. coli O157:H7
isolates were obtained from the cattle in this clinical trial.
By the five primer-pair multiplex PCR, all isolates were
positive for the rfbE and fliCh7 genes; 315 isolates were also
positive for the stx2 and eae genes, but negative for stx1; 42
isolates were positive for all five genes.

4. Discussion
The data presented above demonstrate that virulence factors secreted by the type III system can be used as effective vaccine components for the reduction of colonization
of cattle by E. coli O157:H7 in an experimental challenge
model, and in a clinical trial testing under conditions of
natural exposure within a feedlot setting. These proteins
are major targets of the immune response in humans following infection [22], although calves do not usually mount
a significant serological response against these proteins following natural exposure to the organism. However, cattle
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Figure 4. The proportion of cattle shedding E. coli O157:H7 within
pens of vaccinated and unvaccinated cattle in conditions of natural exposure. Arrows indicate the time of vaccination. Test-periods represent the day of sampling at 3 week intervals (treatment days 0, 21, 42,
63, 84, and the day of marketing), with 0 representing sampling prior
to the first vaccination. Triangles, unvaccinated controls; squares, vaccinated animals.

Figure 3. Percentage of each group of yearling cattle shedding E. coli
O157:H7 (A) and total number of bacteria recovered (B) on each day
after experimental infection. Bacteria were detected in feces by plating on Sorbitol MacConkey agar supplemented with cefixime and tellurite following immunomagnetic enrichment as described [29]. (A)
Solid bars, placebo; hatched bars, EHEC vaccine; open bars, ΔTir vaccine. (B) Squares, placebo group; circles, EHEC vaccine; triangles,
ΔTir vaccine.

vaccinated with these proteins are primed and show an increase in anti-EHEC and anti-Tir titres following oral challenge with the organism [25].
Tir is likely required for colonization of the bovine intestine [25], and this is supported by the observation that a vaccine containing secreted proteins from a ΔTir E. coli O157:
H7 strain was not as efficacious as an identical formulation
from an isogenic wild-type isolate. However, the former vaccine was significantly more efficacious than a placebo suggesting that immunity against colonization is multifactorial
in nature. This is supported by the Western blot analysis of
the response to immunization in which several protein components as well as lipopolysaccharide were recognized.
The clinical trial was conducted under conditions of
natural exposure in an environment typical of feedyards in
the Central US and Canada. The prevalence of E. coli O157:
H7 shedding observed among all of the cattle at the beginning of the trial and among control group cattle throughout
the trial was typical of that previously observed in both research [32] and commercial feedyards [5]. During the trial,
the prevalence of cattle shedding E. coli O157:H7 varied
over time within both treatment groups.

Longitudinal studies have documented that within the
same group of cattle the proportion of cattle shedding E.
coli O157:H7 can vary greatly (1–80%) over the course of
the feeding period [32]. In this study, even though prevalence of shedding varied by time period, vaccination resulted in proportionately less shedding in the five test-periods compared to controls. Three doses of vaccine were
administered during the clinical trial; however, it is not
clear that all three doses were necessary for effect. The
prevalence of shedding was observed to decrease following
the first vaccination in the clinical trial. Also, no interaction
was observed between treatments and test-periods suggesting that the effect of vaccine on fecal shedding did not differ
after the first vaccination. The issue is of practical importance since feedlot operators may be challenged to comply with the need to repeatedly vaccinate cattle, and greater
numbers of doses increase the cost of feedlot cattle production. Therefore, the most efficient number of vaccine doses
must be tested in additional studies. However, the results
of the first vaccine trial in calves described above suggests
that a schedule of two immunizations would be sufficient to
significantly reduce the numbers of animals shedding the
organism.
The prevalence of non-O157 serotypes in North America appears to be increasing and represents a significant
portion of EHEC infections in other geographical locations. Since the type III secreted antigens are relatively
conserved among non-O157 EHEC serotypes, this vaccine
formulation might be broadly cross-protective, in contrast
to formulations based upon the specific O157 LPS antigen.
The vaccine described here is relatively simple and economical to prepare, an essential requirement for any bovine vaccine. In addition, it emphasizes the feasibility of
vaccinating an animal reservoir to potentially decrease human infections.
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